Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
34.7M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
17.2M
-
Shares change
-
+2.51M
-
Total reported value, excl. options
-
$1.52B
-
Value change
-
+$224M
-
Put/Call ratio
-
5.76
-
Number of buys
-
60
-
Number of sells
-
-44
-
Price
-
$88.29
Significant Holders of IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) as of Q4 2020
131 filings reported holding IGMS - IGM Biosciences, Inc. - Common Stock, par value $0.01 per share as of Q4 2020.
IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.2M shares
of 34.7M outstanding shares and own 49.47% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (3.43M shares), BAKER BROS. ADVISORS LP (3.14M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.33M shares), Artal Group S.A. (1.2M shares), ALKEON CAPITAL MANAGEMENT LLC (1.05M shares), RA CAPITAL MANAGEMENT, L.P. (983K shares), BlackRock Inc. (721K shares), Cormorant Asset Management, LP (600K shares), STATE STREET CORP (545K shares), and Woodline Partners LP (540K shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.